Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Evolva appoints Jutta Heim as chief technology officer


Basel, Switzerland, 27th August 2009 - Evolva SA, a Swiss headquartered international biotech company has expanded its Management team by appointing Jutta Heim as Chief Technology Officer. In her new role, Jutta Heim will lead Evolva’s discovery activities and strengthen the development of our technology platform.

Since 2004, Prof. Jutta Heim served as Chief Scientific Officer at Basilea Pharmaceutica AG, a Swiss biopharmaceutical company, where she had responsibility for all discoveries in the areas of anti-infectives, inflammation and oncology. Before Basilea Jutta worked for 22 years for Ciba-Geigy/Novartis (in Switzerland and the USA), where she was involved in the successful development and launch of anti-thrombotic and fibrinolytic products. She established a molecular genetics department in oncology and became Novartis' Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. Jutta completed her career at Novartis by heading the Novartis Lead Discovery Center with worldwide responsibility. She has published numerous papers in the areas of natural products, recombinant proteins and applied molecular biology. Jutta holds a professorship in Biotechnology at the Biocenter of the University of Basel.

Neil Goldsmith, CEO & Managing Director of Evolva, said: “We are very pleased to have Jutta in our Management team. As a Board Member and Chair of the Scientific Advisory Board during the last 4 years, she has already contributed significantly to our development. Her decision to join us as an executive, given her experience in implementing cutting edge discovery approaches at both Basilea and Novartis, will bring strong new competencies to Evolva and to our partners. Her appointment will allow Alexandra SantAna Sorensen, one of the founders of Evolva, to focus on the development of our advancing compound portfolio. Jutta will step down from her position as a non-executive board member of Evolva at the next general meeting.”


About Evolva

Evolva uses its genetic chemistry platform to replicate, on an industrial basis, the ability of nature to create small molecules with exquisite “design”. Based on this technology, Evolva has a number of third party discovery and pre-clinical programs. Evolva also has an attractive pipeline of potential pharmaceutical products deriving from this approach - one compound (for renal and arterial thrombosis) entered Phase I beginning of 2009, and two others (an anti-fungal and an anti-viral) are expected to enter Phase I in 2010. Evolva’s group revenues were c. CHF 10 million in 2008. For more information see www.evolva.com.

Contact Details

Neil Goldsmith, CEO

neilg@evolva.com

Phone: +41 61 485 20 05

Fax: +41 61 485 20 01


Publisher Contact Information:

Evolva SA
+41 61 485 20 05
neilg@evolva.com

Company profile of Evolva SA
Past press releases of Evolva SA.

Data


26,700
Tech investments
From our Online Data Service
17,231
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Feb 21€87.0MInternet services
Feb 21€18.0MInternet commerce
Feb 20€4.3MSoftware development
Feb 19€0.4MInternet commerce
Feb 19€8.4MMedical devices
Feb 18€25.0MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.